Invitrogen

Thermo Fisher Scientific Raises Greenhouse Gas Emissions Reduction Target on Path to Net-zero Emissions

Retrieved on: 
Tuesday, December 6, 2022
Environmental Policy, Professional Services, Health, Environmental Issues, General Health, Environmental, Social and Governance (ESG), Other Science, Research, Environment, Science, Sustainability, Laboratory, Electricity, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, TMO, PPD, Mindful Scientific Inc., Environment, Science, Targets, Paris Agreement, Wind, Patheon, Research, West Pharmaceutical Services explosion, NYSE, Investment, Paris, Applied Biosystems, Multimedia, Health, Renewable energy

This represents an important milestone in Thermo Fishers pursuit of a net-zero value chain by 2050 , which includes Scope 1, 2 and 3 emissions.

Key Points: 
  • This represents an important milestone in Thermo Fishers pursuit of a net-zero value chain by 2050 , which includes Scope 1, 2 and 3 emissions.
  • Our net-zero goal reflects Thermo Fishers commitment to environmental sustainability across the company, said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thermo Fisher Scientific Launches TrueMark Infectious Disease Research Panels

Retrieved on: 
Tuesday, December 6, 2022
Technology, Manufacturing, Other Technology, Other Science, Other Manufacturing, Research, Science, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Infection, PPD, Mindful Scientific Inc., Workflow, Research, Science, TaqMan, Patheon, PCR, West Pharmaceutical Services explosion, Real-time, Real-time polymerase chain reaction, Applied Biosystems, Vertically transmitted infection, Genetic, MagMax, Genetic testing, Health, Vaccine

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TrueMark Infectious Disease Research Panels designed to enable rapid and accurate detection and categorization for investigating microorganisms that cause respiratory, vaginal, urinary, gastrointestinal, and sexually transmitted diseases.
  • TrueMark Infectious Disease Research Panels are analytically sensitive, real-time polymerase chain reaction (PCR) syndromic panels for the analysis of a wide range of infectious disease pathogens.
  • With the TrueMark Infectious Disease Research Panels, laboratories can choose either the readymade panels or create their own custom panels to suit their needs, said Dr. Manoj Gandhi, senior medical director of Genetic Testing Solutions at Thermo Fisher Scientific.
  • For more information on the TrueMark Infectious Disease Research Panels, please visit www.thermofisher.com/truemarkpluspanels .

Thermo Fisher Scientific to Present at Evercore ISI HealthCONx Conference

Retrieved on: 
Monday, November 21, 2022
Medical Supplies, Medical Devices, Health, Other Health, Clinical Trials, Biotechnology, Invitrogen, Applied Biosystems, Thermo Fisher Scientific, TMO, Laboratory, Fisher Scientific, Conference, NYSE, Science, Patheon, Research, Mindful Scientific Inc., Evercore, Diversified Pharmaceutical Services, EST, PPD, Health, Management

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST).

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 10:30 a.m. (EST).
  • You can access the webcast of the presentation via the Investors section of our website, www.thermofisher.com .
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thermo Fisher Scientific Introduces All-in-One AAV Production System for Scalable Gene Therapy Workflows and Commercial Applications

Retrieved on: 
Wednesday, November 16, 2022
Health, Genetics, Other Science, Research, Pharmaceutical, Science, AAV, PEI, Workflow, Invitrogen, Applied Biosystems, Thermo Fisher Scientific, Laboratory, Fisher Scientific, DNA, CTS, Science, Patheon, Cell, HEK293, Research, Transfection, Mindful Scientific Inc., CGMP, West Pharmaceutical Services, PPD, McKinsey & Company, Health, Patient, Vaccine

It features a mammalian-based suspension system comprised of a clonal HEK293 cell line and animal origin-free reagents that support scalable AAV production from shake flask to bioreactor scale.

Key Points: 
  • It features a mammalian-based suspension system comprised of a clonal HEK293 cell line and animal origin-free reagents that support scalable AAV production from shake flask to bioreactor scale.
  • Building on 60 years of trusted Gibco solutions, the CTS AAV-MAX System is the latest addition to our fit-for-purpose line of scalable solutions for commercial manufacturing of cell and gene therapy applications, said Amy Butler, president, biosciences, Thermo Fisher Scientific.
  • As part of Cell Therapy Systems (CTS) solutions, the CTS AAV-MAX System is designed to work within the AAV production workflow , from cell culture and transfection through AAV viral vector production.
  • Researchers can transition seamlessly from research on the Gibco AAV-MAX Helper Free AAV Production System to clinical scale using the CTS AAV-MAX System.

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

Retrieved on: 
Tuesday, November 15, 2022
Science, Other Science, Research, Sale, Invitrogen, Applied Biosystems, Thermo Fisher Scientific, Offering, TMO, Form S-3, Laboratory, Form, Fisher Scientific, Prospectus, KID, NYSE, Deutsche Bank, II, Patheon, Science, Research, Acquisition, Mindful Scientific Inc., Pharmaceutical Services Negotiating Committee, EDGAR, Directive 2014/65/EU, PPD, National identity cards in the European Economic Area, Merrill (company), Health, Public expenditure, Security (finance)

Thermo Fisher Scientific Inc. (NYSE: TMO) (Thermo Fisher) announced today that on November 14, 2022 it priced an offering of 1.25 billion aggregate principal amount (the Offering) of the following euro-denominated notes:

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO) (Thermo Fisher) announced today that on November 14, 2022 it priced an offering of 1.25 billion aggregate principal amount (the Offering) of the following euro-denominated notes:
    500,000,000 aggregate principal amount of its 3.200% senior notes due 2026 (the 2026 notes), at the issue price of 99.965% of their principal amount, and
    750,000,000 aggregate principal amount of its 3.650% senior notes due 2034 (the 2034 notes and together with the 2026 notes, the notes), at the issue price of 99.637% of their principal amount.
  • Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the Offering and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and the Offering.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thermo Fisher Scientific Prices Offering of USD-Denominated Senior Notes

Retrieved on: 
Tuesday, November 15, 2022
Professional Services, Medical Devices, Health, Finance, Pharmaceutical, Biotechnology, BofA Securities, Sale, Deutsche Bank, Invitrogen, Applied Biosystems, Thermo Fisher Scientific, Offering, TMO, Form S-3, Laboratory, Form, Fisher Scientific, Prospectus, NYSE, Science, Patheon, Research, Acquisition, Mindful Scientific Inc., Pharmaceutical Services Negotiating Committee, EDGAR, PPD, Health, Public expenditure, Security (finance)

Thermo Fisher Scientific Inc. (NYSE: TMO) (Thermo Fisher) announced today that on November 14, 2022 it priced an offering of $1.2 billion aggregate principal amount (the Offering) of the following notes:

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO) (Thermo Fisher) announced today that on November 14, 2022 it priced an offering of $1.2 billion aggregate principal amount (the Offering) of the following notes:
    $600 million aggregate principal amount of its 4.800% senior notes due 2027 (the 2027 notes), at the issue price of 99.960% of their principal amount, and
    $600 million aggregate principal amount of its 4.950% senior notes due 2032 (the 2032 notes and together with the 2027 notes, the notes), at the issue price of 99.797% of their principal amount.
  • The joint book-running managers for the Offering are BofA Securities, Inc., Citigroup Global Markets Inc. and Deutsche Bank Securities Inc.
  • Prospective investors should read the prospectus forming a part of that registration statement and the prospectus supplement related to the Offering and the other documents that Thermo Fisher has filed with the SEC for more complete information about Thermo Fisher and the Offering.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

Thermo Fisher Scientific Authorizes $4 Billion of Share Repurchases

Retrieved on: 
Thursday, November 10, 2022
Health, Medical Devices, Health Technology, Research, Science, Pharmaceutical, Biotechnology, Thermo Fisher Scientific, Science, Mindful Scientific Inc., PPD, Research, Patheon, Laboratory, Health, NYSE, Diversified Pharmaceutical Services, TMO, Invitrogen, Applied Biosystems, Fisher Scientific, Management

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its board of directors has authorized the repurchase of $4 billion of shares of its common stock in the open market or in negotiated transactions.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our Mission is to enable our customers to make the world healthier, cleaner and safer.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thermo Fisher Scientific Declares Quarterly Dividend

Retrieved on: 
Thursday, November 10, 2022
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Thermo Fisher Scientific, Laboratory, Health, NYSE, TMO, Patheon, PPD, Research, Board, Board of directors, Diversified Pharmaceutical Services, Science, Invitrogen, Mindful Scientific Inc., Applied Biosystems, Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on January 16, 2023, to shareholders of record as of December 15, 2022.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on January 16, 2023, to shareholders of record as of December 15, 2022.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.
  • Our Mission is to enable our customers to make the world healthier, cleaner and safer.
  • Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Thermo Fisher Scientific and Society for Science Launch Junior Innovators Challenge to Inspire More Than 65,000 Future STEM Leaders Nationwide

Retrieved on: 
Thursday, November 3, 2022
Manufacturing, Other Education, Technology, Primary, Secondary, Pharmaceutical, Education, Philanthropy, Medical Devices, Other Technology, Foundation, Biotechnology, Science, Other Science, Research, Health, Engineering, Research, Foundation, Thermo Fisher Scientific, Student, Multimedia, Education, Mindful Scientific Inc., Product management, Invitrogen, West Pharmaceutical Services explosion, Creativity, Population, NYSE, Applied Biosystems, CEO, Organization, Regeneron Science Talent Search, Society for Science, TMO, Science News, Foundation for Science and Technology, Patheon, Engineering, Partnership, Health, Fisher Scientific, PPD, Technology, Broadcom Inc., Laboratory, News, Learning, Management, Facebook, Science, STEM, Society

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Society for Science (the Society), today announced the Thermo Fisher Scientific Junior Innovators Challenge, the nations premier middle school science, technology, engineering and math (STEM) competition.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Society for Science (the Society), today announced the Thermo Fisher Scientific Junior Innovators Challenge, the nations premier middle school science, technology, engineering and math (STEM) competition.
  • The Society named Thermo Fisher as the new title sponsor of the organizations middle school STEM competition in August .
  • Nearly 300 school, state and regional middle school science fairs across the country have affiliated with the Societys science fair network and will be nominating students to compete in the Thermo Fisher Scientific Junior Innovators Challenge.
  • The announcement of the Junior Innovators Challenge aligns with Thermo Fishers annual STEM Education Month campaign, which runs throughout November.

Thermo Fisher Scientific Continues to Execute Proven Capital Deployment Strategy

Retrieved on: 
Monday, October 31, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Health, Medical Devices, Health Technology, Other Health, Invitrogen, PPD, Share repurchase, Intellectual property, Government, Thermo Fisher Scientific, Research, West Pharmaceutical Services explosion, U.S. Securities and Exchange Commission, TMO, SEC, NYSE, Patheon, SEC filing, Applied Biosystems, Growth, Acquisition, Fisher Scientific, Form 10-K, Binding site, Communication, Mindful Scientific Inc., Annual report, COVID-19, Health, Laboratory, Science, Renewable energy, Risk management

Thermo Fisher Scientific Inc. (NYSE: TMO) (Thermo Fisher), the world leader in serving science, today provided an update on capital deployment.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO) (Thermo Fisher), the world leader in serving science, today provided an update on capital deployment.
  • Throughout the fourth quarter of 2022, Thermo Fisher expects to execute a $1.0 billion share repurchase program, bringing the total capital deployed on buybacks to $3.0 billion in 2022.
  • Thermo Fisher continues to execute its disciplined capital deployment strategy through a combination of strategic M&A and return of capital to shareholders.
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.